Citarinostat

DB15449InvestigationalSmall molecule

Citarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM).

Chemical structure of Citarinostat
Formula / weight
C24H26ClN5O3 · 467.95 g/mol (avg)

Resolves to

Compound
UNII441P620G3PCAS1316215-12-9ChEMBLCHEMBL3693786
Structure
InChIKeyVLIUIBXPEDFJRF-UHFFFAOYSA-NSMILESONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1Cl
Targets
Q9UBN7HDAC6

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Citarinostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In